Logotype for Autolus Therapeutics plc

Autolus Therapeutics (AUTL) Q4 2023 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Autolus Therapeutics plc

Q4 2023 earnings summary

9 Nov, 2026

Executive summary

  • Obe-cel’s U.S. BLA was accepted with a November 16, 2024 PDUFA date; an EMA marketing application was submitted, and launch preparation continued.

  • FELIX analyses showed stronger event-free survival with lower leukemic burden and low rates of high-grade CRS/ICANS; pooled long-term follow-up reported an 80.6% ORR in R/R B-ALL.

  • Year-end cash was $239.6M; February financing and the BioNTech collaboration generated $600M in gross proceeds to support launch and pipeline development.

Financial highlights

  • FY23 operating expenses, net, were $179.7M vs. $143.4M in FY22; R&D was $130.5M vs. $117.4M and G&A was $46.7M vs. $31.9M.

  • FY23 net loss was $208.4M vs. $148.8M in FY22; basic and diluted loss per share was $1.20 vs. $1.57.

  • FY23 license revenue was $1.7M vs. $6.2M in FY22; interest income was $13.5M vs. $1.7M and interest expense was $45.1M vs. $8.9M.

  • Cash and cash equivalents were $239.6M at December 31, 2023, vs. $382.4M at December 31, 2022.

Outlook and guidance

  • FDA action on obe-cel is targeted for November 16, 2024; an MHRA application filing was planned for H2 2024, with U.S. launch preparation and center onboarding underway.

  • 2024 milestones included obe-cel FELIX updates at ASCO, EHA and ASH; initial Phase 1 SLE data were expected in late 2024.

  • Initial AUTO8 MCARTY study data were expected during 2024; cash and February financing proceeds were expected to fund launch preparations, pipeline development and autoimmune studies.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Autolus Therapeutics